Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)
ID: 353369Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $275K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353369

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-TR-24-023.html
Timeline
  1. 1
    Forecast Posted Not available
  2. 2
    Forecast Due Not available
  3. 3
    Posted Apr 3, 2024 12:00 AM
  4. 4
    Due Jun 2, 2026 12:00 AM
Description

The National Institutes of Health (NIH) is offering a grant opportunity titled "Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)". This grant aims to provide funding for conducting efficacy studies in an established rare disease preclinical model. The goal is to demonstrate that a proposed therapeutic agent warrants further development. The supported studies will include preclinical efficacy, as well as accompanying pharmacodynamic and pharmacokinetic studies. The therapeutic agents can include small molecules, biologics, or biotechnology-derived products. The ultimate objective of this grant is to advance projects to a stage where they would attract subsequent investment for full Investigational New Drug (IND) application development or progression to clinical trials, particularly for repurposing or repositioning purposes. The grant has a maximum award ceiling of $275,000 and does not require cost sharing or matching. The eligibility criteria include various types of institutions and organizations, such as Alaska Native and Native Hawaiian Serving Institutions, Faith-based or Community-based Organizations, and U.S. Territories or Possessions. Non-domestic (non-U.S.) entities and components are not eligible to apply. The deadline for application submission is June 2, 2026. For more information and to apply, please visit the following link: Preclinical Proof of Concept Studies for Rare Diseases Grant. For any inquiries, please contact NIH Grants Information at grantsinfo@nih.gov.

Point(s) of Contact
grantsinfo@nih.gov
Files
Title
Posted
RFA-TR-24-023.html
4/20/2024
Similar Opportunities
Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed)
Active
National Institutes of Health
The National Institutes of Health is offering a grant opportunity titled "Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed)". This grant aims to support clinical projects that address critical needs for clinical trial readiness in rare diseases. The funding will enable the efficient and effective movement of candidate therapeutics or diagnostics towards clinical trials, increase the likelihood of success through the development and testing of rigorous biomarkers and clinical outcome assessment measures, and enable the design of upcoming clinical trials by defining the presentation and course of a rare disease. The grant does not require cost sharing or matching. The maximum award ceiling is $275,000. Other eligible applicants include Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions, Eligible Agencies of the Federal Government, Faith-based or Community-based Organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities, Indian/Native American Tribal Governments, Non-domestic Entities, Regional Organizations, Tribally Controlled Colleges and Universities, U.S. Territories or Possessions. Non-domestic entities and components of U.S. organizations are not eligible to apply. The deadline for application submission is October 17, 2024. For more information and to apply, visit the following link: [Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes Grant](http://grants.nih.gov/grants/guide/pa-files/PAR-23-159.html). For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R03 Clinical Trial Not Allowed)
Active
National Institutes of Health
The National Institutes of Health is offering a grant opportunity titled "Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R03 Clinical Trial Not Allowed)". This grant aims to support clinical projects that address critical needs for clinical trial readiness in rare diseases. The funding will enable the efficient and effective movement of candidate therapeutics or diagnostics towards clinical trials, increase the likelihood of success through the development and testing of rigorous biomarkers and clinical outcome assessment measures, and enable the design of upcoming clinical trials by defining the presentation and course of a rare disease. The grant does not require cost sharing or matching. The maximum award ceiling is $100,000. The deadline for application submission is October 17, 2024. For more information and to apply, please visit the following link: [Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes Grant](http://grants.nih.gov/grants/guide/pa-files/PAR-23-160.html).
Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN) (U54 Clinical Trial Optional)
Active
National Institutes of Health
The National Institutes of Health is offering a grant opportunity titled "Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN) (U54 Clinical Trial Optional)". This grant aims to invite new and renewal applications for the Rare Diseases Clinical Research Consortia (RDCRC) that comprise the Rare Diseases Clinical Research Network (RDCRN). The objective of this grant is to advance and improve the diagnosis, management, and treatment of numerous, diverse rare diseases through highly collaborative, multi-site, patient-centric, translational, and clinical research. Special emphasis will be placed on the early and timely identification of individuals with rare diseases and clinical trial readiness. The grant does not require cost sharing or matching requirements and falls under the category of Income Security and Social Services. The maximum award ceiling is $1,000,000. The grant is open to various eligible applicants, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Eligible Agencies of the Federal Government, Faith-based or Community-based Organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), Non-domestic (non-U.S.) Entities (Foreign Organizations), Regional Organizations, Tribally Controlled Colleges and Universities (TCCUs), U.S. Territory or Possession. Non-domestic (non-U.S.) Entities (Foreign Organization) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are also not eligible to apply. The grant opportunity will close on August 13, 2024, and the archive date is set for September 18, 2024. For more information and to apply, please visit the following link: [http://grants.nih.gov/grants/guide/pa-files/PAR-24-206.html](http://grants.nih.gov/grants/guide/pa-files/PAR-24-206.html). For any inquiries, please contact NIH Grants Information at grantsinfo@nih.gov.
Clinical Trial Readiness for Rare Neurological and Neuromuscular Diseases (U01 Clinical Trial Not Allowed)
Active
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Clinical Trial Readiness for Rare Neurological and Neuromuscular Diseases (U01 Clinical Trial Not Allowed)". This grant opportunity falls under the category of Health and is a Cooperative Agreement. The grant does not require cost sharing or matching. The maximum award ceiling for this grant is $750,000. The eligible applicants for this grant include various institutions and organizations such as Alaska Native and Native Hawaiian Serving Institutions, Faith-based or Community-based Organizations, and U.S. Territories or Possessions. The purpose of this grant is to support clinical trial readiness for rare neurological and neuromuscular diseases. The grant aims to fund projects that will enhance the understanding of these diseases and develop strategies for their diagnosis, treatment, and prevention. For more information and to apply for this grant, please visit the following link: [http://grants.nih.gov/grants/guide/pa-files/PAR-22-184.html](http://grants.nih.gov/grants/guide/pa-files/PAR-22-184.html).
Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)
Active
National Institutes of Health
The National Institutes of Health (NIH) is offering a grant opportunity titled "Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)". This grant aims to support the development and implementation of investigator-initiated single site clinical trials, including efficacy, comparative effectiveness, pragmatic, and/or implementation research clinical trials. The trials funded by this opportunity must be relevant to the research mission of the NHLBI (National Heart, Lung, and Blood Institute) and meet the NIH definition of a clinical trial. The purpose of these trials is to test different therapeutic, behavioral, and/or prevention strategies. Applicants are encouraged to consult the NHLBI website for more information about the mission, strategic vision, and research priorities of the institute. The funding will be provided through a bi-phasic, milestone-driven mechanism of award. Applicants should present a scientific rationale for the clinical trial and a comprehensive scientific and operational plan. The plan should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. While the multiple PD/PI (Principal Investigator) model is strongly encouraged, it is not required. Applicants are also encouraged to include a PD/PI with expertise in biostatistics, clinical trial design, and coordination. The grant opportunity is open to various eligible applicants, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Eligible Agencies of the Federal Government, Faith-based or Community-based Organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), Non-domestic (non-U.S.) Entities (Foreign Organizations), Regional Organizations, Tribally Controlled Colleges and Universities (TCCUs), and U.S. Territory or Possession. The deadline for submitting applications is September 11, 2025. For more information and to apply, please visit the following link: [http://grants.nih.gov/grants/guide/pa-files/PAR-22-189.html](http://grants.nih.gov/grants/guide/pa-files/PAR-22-189.html). If you have any inquiries, please refer to the contact information provided in Section VII of the full opportunity announcement or email OERWebmaster03@od.nih.gov.